You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Danek P, Simonova E, Podzimkova N, et al
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0713